Diabetes & Endocrinology
Latest news
609 articles · 20 / page
Evaluating Selenium Supplementation in Gestational Diabetes Mellitus: Insights from a Systematic Review and Meta-Analysis
Selenium supplementation at 200 µg/d may reduce fasting plasma glucose and newborn hyperbilirubinemia risk in gestational diabetes without significantly altering lipid profiles, highlighting potential but limited benefits requiring further
Optimizing Antithymocyte Globulin Dose for Preserving Beta-Cell Function in Recent-Onset Type 1 Diabetes: Insights from the MELD-ATG Trial
The MELD-ATG phase 2 trial identifies low-dose antithymocyte globulin as an effective and safe intervention to reduce beta-cell loss in young people with recent-onset type 1 diabetes, highlighting a potential disease-modifying therapy.
Tirzepatide Shows Promising Efficacy and Safety in Managing Youth-Onset Type 2 Diabetes: Insights from the SURPASS-PEDS Trial
The phase 3 SURPASS-PEDS trial demonstrates that tirzepatide significantly improves glycaemic control and reduces BMI in children and adolescents with type 2 diabetes, with a safety profile consistent with adult studies.
Evaluating Myo-Inositol Supplementation for Preventing Pregnancy Complications in PCOS: Insights from a Robust Randomized Trial
A large randomized clinical trial found that myo-inositol supplementation during pregnancy in individuals with PCOS did not significantly reduce rates of gestational diabetes, preeclampsia, or preterm birth compared to placebo.
Patterns and Predictors of GLP-1 Agonist Use After Bariatric Surgery in US Adults
A large US cohort study reveals that 14% of bariatric surgery patients start GLP-1 receptor agonists postoperatively, with higher use seen among women, sleeve gastrectomy recipients, and those with greater BMI regain.
Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis
A phase 2b trial demonstrates that several noninvasive tests reliably reflect treatment response to semaglutide in patients with metabolic dysfunction-associated steatohepatitis, correlating with histologic improvements over 72 weeks.
Preserving Bone Quality in Older Adults with Obesity Through Lifestyle Intervention: Insights from the LIMB-Q Trial
The LIMB-Q trial demonstrates that intensive lifestyle interventions combining weight management and exercise preserve bone quality in older adults with obesity, despite significant weight loss, highlighting a promising approach for mitigat
Acute Angle Closure Incidence in a Large Countywide Safety Net Teleretinal Screening Program: Safety of Pharmacologic Dilation in Diabetic Retinopathy Screening
This review synthesizes evidence on the incidence of acute angle closure (AAC) following pharmacologic pupillary dilation in a large teleretinal screening program, confirming the very low risk and supporting dilation safety in diverse popul
Cutaneous Presentation of Hyperthyroidism in a Middle-aged Female: A Case Report
A 45-year-old female presented with pruritic skin lesions and weight loss, diagnosed with hyperthyroidism manifesting cutaneous symptoms. Treatment with antithyroid medication led to symptom resolution.
Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Patients with Heart Failure: Prevalence, Genetics, and Clinical Implications
A prospective study reveals transthyretin cardiac amyloidosis (ATTR-CA) affects a significant proportion of older Black patients with heart failure, especially men over 75, with nearly half linked to the V142I genetic variant. Hispanic prev
Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management
Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies
What’s New in the ADA 2024 Standards of Care: Practical Guidance on Weight‑Lowering Drugs, Cardiorenal Protection, and Technology for Diabetes
The ADA 2024 Standards update care pathways for diabetes with stronger guidance on obesity pharmacotherapy (GLP‑1/GIP agents), earlier use of SGLT2/GLP‑1 for cardiorenal benefit, and expanded technology recommendations.
Promising Links Between Diabetes Medications and Alzheimer’s Disease Risk Reduction
Recent real-world data suggest GLP-1 receptor agonists and SGLT2 inhibitors may lower Alzheimer’s disease risk more effectively than DPP-4 inhibitors, highlighting the need for randomized trials to confirm potential neuroprotective benefits
Long-term Stroke Risk in Chinese Adults with Newly Diagnosed Diabetes and Impaired Glucose Tolerance: Insights from the 34-Year Da Qing Diabetes Study
A 34-year follow-up of the Da Qing Diabetes Study reveals significantly increased stroke incidence among Chinese adults with newly diagnosed type 2 diabetes and impaired glucose tolerance, highlighting the beneficial impact of lifestyle int
Rapirosiran: A Promising RNA Interference Therapy Targeting HSD17B13 for Metabolic Dysfunction-Associated Steatohepatitis
This phase I randomized study shows rapirosiran, an RNAi therapeutic targeting HSD17B13, is safe and effectively reduces liver HSD17B13 mRNA in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Enhancing Graves’ Disease Treatment: The Benefits of Adding L-Carnitine and Selenium to Methimazole Therapy
A recent randomized trial shows that supplementing methimazole with L-carnitine and selenium in Graves’ disease shortens disease duration, lowers antibody levels faster, reduces medication dose, and improves select symptoms, highlighting a
Tirzepatide Influences Muscle Composition Favorably Amid Weight Loss in Type 2 Diabetes: Insights from SURPASS-3 MRI Substudy
In type 2 diabetes patients, tirzepatide treatment led to significant reductions in muscle fat infiltration and adaptive decreases in muscle volume over 52 weeks, suggesting beneficial effects on muscle health concurrent with weight loss.
Henagliflozin and Aging Biomarkers in Type 2 Diabetes: A Groundbreaking Multicenter Trial Reveals Promising Anti-Aging Effects
A randomized placebo-controlled trial demonstrates that henagliflozin improves telomere length and multiple aging biomarkers in patients with type 2 diabetes, suggesting potential anti-aging benefits beyond glucose control.
Fulmetibant’s Role in Diabetic Neuropathic Pain: Insights from the Phase 2a BRADiNP Study
The BRADiNP study found that fulmetibant, a bradykinin-1 receptor antagonist, failed to significantly reduce diabetic neuropathic pain compared to placebo, despite favorable safety profiles, highlighting challenges in translating preclinica
Browse by specialty
Open language-specific specialty feeds and department pages.